S&P 500   3,116.01 (-0.19%)
DOW   27,905.12 (-0.47%)
QQQ   202.84 (-0.11%)
CGC   15.11 (+6.26%)
BABA   184.43 (-0.10%)
GE   11.32 (-1.05%)
T   38.43 (-3.05%)
ACB   2.35 (+3.07%)
F   8.91 (-0.45%)
PRI   131.19 (+0.07%)
BAC   32.86 (-0.30%)
S&P 500   3,116.01 (-0.19%)
DOW   27,905.12 (-0.47%)
QQQ   202.84 (-0.11%)
CGC   15.11 (+6.26%)
BABA   184.43 (-0.10%)
GE   11.32 (-1.05%)
T   38.43 (-3.05%)
ACB   2.35 (+3.07%)
F   8.91 (-0.45%)
PRI   131.19 (+0.07%)
BAC   32.86 (-0.30%)
S&P 500   3,116.01 (-0.19%)
DOW   27,905.12 (-0.47%)
QQQ   202.84 (-0.11%)
CGC   15.11 (+6.26%)
BABA   184.43 (-0.10%)
GE   11.32 (-1.05%)
T   38.43 (-3.05%)
ACB   2.35 (+3.07%)
F   8.91 (-0.45%)
PRI   131.19 (+0.07%)
BAC   32.86 (-0.30%)
S&P 500   3,116.01 (-0.19%)
DOW   27,905.12 (-0.47%)
QQQ   202.84 (-0.11%)
CGC   15.11 (+6.26%)
BABA   184.43 (-0.10%)
GE   11.32 (-1.05%)
T   38.43 (-3.05%)
ACB   2.35 (+3.07%)
F   8.91 (-0.45%)
PRI   131.19 (+0.07%)
BAC   32.86 (-0.30%)
Log in

Zoetis Stock Price, Forecast & Analysis (NYSE:ZTS)

$118.87
+0.07 (+0.06 %)
(As of 11/19/2019 11:10 AM ET)
Today's Range
$118.57
Now: $118.87
$119.53
50-Day Range
$116.17
MA: $124.10
$129.65
52-Week Range
$78.90
Now: $118.87
$130.20
Volume14,068 shs
Average Volume2.50 million shs
Market Capitalization$56.62 billion
P/E Ratio37.98
Dividend Yield0.56%
Beta0.88
Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that prevent or eliminate external and internal parasites that include fleas, ticks, and worms. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
CUSIP98978V10
Phone973-822-7000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$5.83 billion
Cash Flow$3.85 per share
Book Value$4.55 per share

Profitability

Net Income$1.43 billion

Miscellaneous

Employees10,000
Market Cap$56.62 billion
Next Earnings Date2/13/2020 (Estimated)
OptionableOptionable

Receive ZTS News and Ratings via Email

Sign-up to receive the latest news and ratings for ZTS and its competitors with MarketBeat's FREE daily newsletter.


Zoetis (NYSE:ZTS) Frequently Asked Questions

What is Zoetis' stock symbol?

Zoetis trades on the New York Stock Exchange (NYSE) under the ticker symbol "ZTS."

How often does Zoetis pay dividends? What is the dividend yield for Zoetis?

Zoetis declared a quarterly dividend on Thursday, October 3rd. Stockholders of record on Tuesday, October 22nd will be given a dividend of $0.164 per share on Monday, December 2nd. This represents a $0.66 dividend on an annualized basis and a dividend yield of 0.55%. The ex-dividend date of this dividend is Monday, October 21st. View Zoetis' Dividend History.

How will Zoetis' stock buyback program work?

Zoetis declared that its board has authorized a stock repurchase program on Wednesday, December 12th 2018, which authorizes the company to repurchase $2,000,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization authorizes the company to buy up to 4.7% of its stock through open market purchases. Stock repurchase programs are typically a sign that the company's board of directors believes its shares are undervalued.

How were Zoetis' earnings last quarter?

Zoetis Inc (NYSE:ZTS) released its quarterly earnings results on Thursday, November, 7th. The company reported $0.94 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $0.88 by $0.06. The business earned $1.58 billion during the quarter, compared to analyst estimates of $1.58 billion. Zoetis had a net margin of 23.76% and a return on equity of 70.78%. The firm's quarterly revenue was up 7.0% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.83 earnings per share. View Zoetis' Earnings History.

When is Zoetis' next earnings date?

Zoetis is scheduled to release their next quarterly earnings announcement on Thursday, February 13th 2020. View Earnings Estimates for Zoetis.

What guidance has Zoetis issued on next quarter's earnings?

Zoetis issued an update on its FY19 earnings guidance on Thursday, November, 7th. The company provided EPS guidance of $3.57-3.62 for the period, compared to the Thomson Reuters consensus EPS estimate of $3.57. The company issued revenue guidance of $6.24 billion, compared to the consensus revenue estimate of prior $3.53-3.60.

What price target have analysts set for ZTS?

15 Wall Street analysts have issued 12-month target prices for Zoetis' shares. Their forecasts range from $86.00 to $150.00. On average, they expect Zoetis' stock price to reach $127.67 in the next year. This suggests a possible upside of 7.2% from the stock's current price. View Analyst Price Targets for Zoetis.

What is the consensus analysts' recommendation for Zoetis?

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zoetis in the last year. There are currently 6 hold ratings, 8 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Zoetis.

Has Zoetis been receiving favorable news coverage?

Press coverage about ZTS stock has trended somewhat positive recently, InfoTrie reports. The research firm rates the sentiment of news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Zoetis earned a media sentiment score of 1.1 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 1.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for Zoetis.

Are investors shorting Zoetis?

Zoetis saw a drop in short interest in October. As of October 15th, there was short interest totalling 3,970,000 shares, a drop of 10.2% from the September 15th total of 4,420,000 shares. Based on an average daily volume of 1,960,000 shares, the days-to-cover ratio is presently 2.0 days. Currently, 0.8% of the company's stock are short sold. View Zoetis' Current Options Chain.

Who are some of Zoetis' key competitors?

What other stocks do shareholders of Zoetis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Zoetis investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Hawkins (HWKN), Chipotle Mexican Grill (CMG), Aegean Marine Petroleum Network (ANW), Athabasca Oil (ATH), Transocean (RIG), Micron Technology (MU) and Gran Tierra Energy (GTE).

Who are Zoetis' key executives?

Zoetis' management team includes the folowing people:
  • Mr. Juan Ramón Alaix, CEO & Director (Age 68)
  • Mr. Glenn C. David, Exec. VP & CFO (Age 47)
  • Dr. Catherine A. Knupp, Exec. VP and Pres of R&D (Age 58)
  • Mr. Clinton A. Lewis Jr., EVP and Grp Pres of Intl. Ops., Comm. Devp., Glbl Genetics, Aquatic Health & Human Medical Digs (Age 52)
  • Ms. Kristin C. Peck, Exec. VP and Group Pres of U.S. Operations, Bus. Devel. & Strategy (Age 48)

Who are Zoetis' major shareholders?

Zoetis' stock is owned by many different of retail and institutional investors. Top institutional investors include Massachusetts Financial Services Co. MA (1.58%), Cantillon Capital Management LLC (0.77%), California Public Employees Retirement System (0.50%), CIBC Private Wealth Group LLC (0.49%), Sumitomo Mitsui Trust Holdings Inc. (0.41%) and Public Employees Retirement Association of Colorado (0.32%). Company insiders that own Zoetis stock include Catherine A Knupp, Clinton A Jr Lewis, Glenn David, Heidi C Chen, Juan Ramon Alaix, Khosla Sanjay, Kristin C Peck, Roman Trawicki, Roxanne Lagano and Willie M Reed. View Institutional Ownership Trends for Zoetis.

Which major investors are selling Zoetis stock?

ZTS stock was sold by a variety of institutional investors in the last quarter, including Ardevora Asset Management LLP, State of New Jersey Common Pension Fund D, Artemis Investment Management LLP, Massachusetts Financial Services Co. MA, AMF Pensionsforsakring AB, Russell Investments Group Ltd., Strs Ohio and Congress Asset Management Co. MA. Company insiders that have sold Zoetis company stock in the last year include Catherine A Knupp, Clinton A Jr Lewis, Glenn David, Heidi C Chen, Juan Ramon Alaix, Kristin C Peck, Roman Trawicki, Roxanne Lagano and Willie M Reed. View Insider Buying and Selling for Zoetis.

Which major investors are buying Zoetis stock?

ZTS stock was bought by a variety of institutional investors in the last quarter, including California Public Employees Retirement System, CIBC Private Wealth Group LLC, Sumitomo Mitsui Trust Holdings Inc., State of Tennessee Treasury Department, Railway Pension Investments Ltd, Jag Capital Management LLC, First Trust Advisors LP and Robeco Institutional Asset Management B.V.. View Insider Buying and Selling for Zoetis.

How do I buy shares of Zoetis?

Shares of ZTS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Zoetis' stock price today?

One share of ZTS stock can currently be purchased for approximately $119.06.

How big of a company is Zoetis?

Zoetis has a market capitalization of $56.71 billion and generates $5.83 billion in revenue each year. The company earns $1.43 billion in net income (profit) each year or $3.13 on an earnings per share basis. Zoetis employs 10,000 workers across the globe.View Additional Information About Zoetis.

What is Zoetis' official website?

The official website for Zoetis is http://www.zoetis.com/.

How can I contact Zoetis?

Zoetis' mailing address is 10 Sylvan Way, Parsippany NJ, 07054. The company can be reached via phone at 973-822-7000 or via email at [email protected]


MarketBeat Community Rating for Zoetis (NYSE ZTS)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  725 (Vote Outperform)
Underperform Votes:  434 (Vote Underperform)
Total Votes:  1,159
MarketBeat's community ratings are surveys of what our community members think about Zoetis and other stocks. Vote "Outperform" if you believe ZTS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZTS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/19/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel